Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the occurrence rate of the high pressure phase and the final pressure outcomes between patients treated with glaucoma medication prior to the expected onset of the high pressure phase to those patients who have glaucoma medication started at the onset of the high pressure phase. The investigators hypothesize that if glaucoma medications are started prior to the expected onset of high pressure phase, the high pressure phase will not occur as frequently and the ultimate pressure level will be lower than if the glaucoma medications are started at the onset of this phase.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Los Angeles
• Treatments: Brimonidine Tartrate; Brinzolamide; Dorzolamide; Timolol

Criteria

Inclusion Criteria:

1. Patients requiring Ahmed glaucoma valve implantation to control intraocular pressure between the ages of 18 and 85 years.

Exclusion Criteria:

1. Unwilling or unable to give consent or unwilling to accept randomization.

2. Patient out of area and potentially unavailable for follow-up visits.

3. Known allergic reaction to timolol, brimonidine, dorzolamide, brinzolamide, or sulfa drugs.

4. Known medical contraindications to the use of beta-blockers, including congestive heart failure, heart block, asthma, and chronic obstructive pulmonary disease.

5. Concurrent intraocular procedure with Ahmed glaucoma valve implantation

6. Previous Ahmed glaucoma valve implantation